Osteoclasts resorb the mineralized matrices formed by chondrocytes or osteoblasts. The cytokine receptor activator of nuclear factor-κB ligand (RANKL) is essential for osteoclast formation and thought to be supplied by osteoblasts or their precursors, thereby linking bone formation to resorption. However, RANKL is expressed by a variety of cell types, and it is unclear which of them are essential sources for osteoclast formation. Here we have used a mouse strain in which RANKL can be conditionally deleted and a series of Cre-deleter strains to demonstrate that hypertrophic chondrocytes and osteocytes, both of which are embedded in matrix, are essential sources of the RANKL that controls mineralized cartilage resorption and bone remodeling, respectively. Moreover, osteocyte RANKL is responsible for the bone loss associated with unloading. Contrary to the current paradigm, RANKL produced by osteoblasts or their progenitors does not contribute to adult bone remodeling. These results suggest that the rate-limiting step of matrix resorption is controlled by cells embedded within the matrix itself.
a r t i c l e s
Resorption of cartilage and bone is essential for development and regeneration of the skeleton. During longitudinal bone growth, calcified cartilage produced by chondrocytes is resorbed by osteoclasts and replaced by a bone matrix made by osteoblasts in a process known as endochondral bone formation 1 . After growth, older bone is periodically resorbed by osteoclasts and newer bone is deposited in the resulting cavities by osteoblasts in a process known as remodeling 2 . Osteoclasts are multinucleated cells derived from the monocyte-macrophage lineage and are primarily responsible for resorption of mineralized matrices 3 . Excessive bone resorption causes the most common bone disorders, including osteoporosis, Paget's disease and osteolysis from cancer 2, 4, 5 .
The cytokine RANKL (encoded by the Tnfsf11 gene) initiates osteoclast differentiation and is essential for their development, function and survival 6, 7 . According to the prevailing paradigm, osteoblasts on the bone surface, or their progenitors in the marrow, supply the RANKL responsible for osteoclast generation [8] [9] [10] [11] . But this idea is based primarily on in vitro experiments demonstrating that osteoblast progenitors support osteoclast formation 12 . Despite the lack of in vivo evidence, the concept that osteoblasts or their progenitors control osteoclast generation has gained wide acceptance over the past 30 years and has been used to explain how bone formation is linked to bone resorption during remodeling 9, 11, 13 . However, several observations suggest that matrixsynthesizing osteoblasts are not essential for osteoclast formation, and therefore may not be a major source of RANKL. First, targeted ablation of osteoblasts in transgenic mice does not reduce osteoclast number or RANKL expression 14, 15 . Second, a variety of genetic modifications in mice alter osteoblast number without changing osteoclast number [16] [17] [18] . And third, administration of glucocorticoids potently reduces the number of osteoblasts on bone, as well as the abundance of their precursors in the bone marrow, but not the number of osteoclasts 19, 20 .
To identify the cellular sources of RANKL during bone growth and remodeling, we generated mice in which RANKL can be conditionally deleted and crossed them with several lines of transgenic mice expressing Cre recombinase in genetically defined cell populations representing different stages of osteoblast and chondrocyte differentiation. We report that hypertrophic chondrocytes, which are buried within mineralized cartilage, supply RANKL during bone growth. Moreover, osteocytes, former osteoblasts buried within mineralized bone that sense and respond to changes in mechanical forces, are an essential source of RANKL during bone remodeling. Consistent with this finding, mice lacking RANKL in osteocytes are protected from bone loss owing to unloading. Thus, the resorption that occurs during both bone development and remodeling is orchestrated by matrix-embedded cells via production of the rate-limiting factor for osteoclast differentiation and function.
RESULTS

Mesenchymal cell RANKL is essential for osteoclastogenesis
To allow deletion of RANKL in various genetically defined cell populations, we generated mice harboring a Tnfsf11 allele in which exons 3 and 4 were flanked by loxP sites, hereafter called RANKLf/f mice (Supplementary Fig. 1 ). To determine whether RANKL expression in cells of the mesenchymal lineage is required for osteoclast formation, we crossed RANKLf/f mice with transgenic mice expressing Cre recombinase under the control of Prrx1 regulatory elements, hereafter called Prx1-Cre mice. Prx1-Cre mice express Cre recombinase in the mesenchymal condensations that form the developing limbs and parts of the skull, but not in the spine or other organs 21 . RANKL mRNA levels were significantly lower in the tibia and calvaria, but not in the vertebra or spleen, of 5-week-old Prx1-Cre;RANKLf/f mice as compared with RANKLf/f littermates, confirming deletion in the expected tissues (Fig. 1a) .
Consistent with the changes in RANKL expression, Prx1-Cre;RANKLf/f mice had greater bone mineral density (BMD) and cancellous bone volume in the femur (Fig. 1b,c) , but not in the spine (Supplementary Fig. 2 ), than RANKLf/f littermates. Bone mass a r t i c l e s was similar in Prx1-Cre, RANKLf/f and wild-type (WT) littermates (Fig. 1b,c) , demonstrating that the Prx1-Cre transgene and the Tnfsf11 conditional allele had no impact on the skeleton. Therefore, we carried out all subsequent analyses by comparing only RANKLf/f and Prx1-Cre;RANKLf/f littermates. High-resolution microcomputed tomography (µCT) analysis of the distal femur showed severe osteopetrosis in Prx1-Cre;RANKLf/f mice (Fig. 1d) . Safranin O staining, which specifically detects cartilage, showed large amounts of unresorbed cartilage and widened growth plates in the femurs of Prx1-Cre;RANKLf/f mice (Fig. 1e) , similar to observations in mice with germline deletion of either RANKL or its receptor RANK 6, 22 . Moreover, osteoclasts were completely absent in the femurs of Prx1-Cre;RANKLf/f mice, whereas they were abundant in control littermates (Fig. 1f) . Consistent with this, osteoclast-specific gene expression was notably lower in the conditional knockout mice than in control littermates (Fig. 1g) . These results demonstrate that RANKL expression in mesenchyme-derived cells is essential for all osteoclast formation in growing long bones. Tooth eruption, which also requires osteoclast activity 6 , was normal in Prx1-Cre;RANKLf/f mice ( Supplementary Fig. 2) , demonstrating that the Prx1-Cre expression in the skull does not occur in cells that produce the RANKL required for this process.
Loss of chondrocyte RANKL is associated with osteopetrosis
The Prx1-Cre transgene causes deletion in both chondrocytes and osteoblast-lineage cells (Supplementary Fig. 2) . To determine the contribution of these cell types, we compared the skeletal phenotypes of mice in which RANKL was deleted using transgenes in which Cre recombinase was under the control of regulatory elements of the following genes: Sp7 (Sp7-Cre), hereafter called osterix 1 (Osx1)-Cre mice; BGLAP (BGLAP-Cre), hereafter called osteocalcin (Ocn)-Cre mice or Dmp1, hereafter called dentin matrix protein 1 (Dmp1)-Cre mice. The Osx1-Cre transgene becomes active at the earliest stages of osteoblast differentiation and in late-proliferating chondrocytes 23, 24 . Ocn-Cre is active in mature osteoblasts 25 , and Dmp1-Cre in osteocytes 26 . Because these transgenes become active at different stages of osteoblast differentiation, and because only some have activity in chondrocytes, we reasoned that their use with the Tnfsf11 conditional allele might identify essential cellular sources of RANKL for osteoclast formation.
RANKL mRNA expression was lower in bones from Osx1-Cre;RANKLf/f and Ocn-Cre;RANKLf/f mice, but not from Dmp1-Cre;RANKLf/f mice, compared with control littermates (Fig. 2a) . However, we detected deletion of the Tnfsf11 conditional allele in cortical bone from Dmp1-Cre;RANKLf/f mice (Fig. 2b) . RANKL mRNA abundance was unaffected in the spleens of all three models, demonstrating the specificity of deletion (Supplementary Fig. 3 ). Cancellous bone volume, measured by µCT when mice were 5 weeks old, was much higher in Osx1-Cre;RANKLf/f and Ocn-Cre;RANKLf/f mice, but not in Dmp1-Cre;RANKLf/f mice, compared with control littermates (Fig. 2c) . We compared the BMD of WT littermates with littermates harboring only Cre transgenes and found that the high bone mass was not associated with the transgenes alone ( Supplementary  Fig. 3 ). Tooth eruption was completely absent in Osx1-Cre;RANKLf/f mice, occurred in some but not all Ocn-Cre;RANKLf/f mice and was normal in Dmp1-Cre;RANKLf/f mice (Fig. 2d) . Large amounts of unresorbed calcified cartilage and widened growth plates were present in Osx1-Cre;RANKLf/f and Ocn-Cre;RANKLf/f femurs, whereas normal cancellous bone and growth plates were present in Dmp1-Cre;RANKLf/f mice (Fig. 2d) . Consistent with this, osteoclast abundance (Fig. 2d) and osteoclast-specific gene expression (Supplementary Fig. 3 ) were lower in Osx1-Cre;RANKLf/f and OcnCre;RANKLf/f mice, but not in Dmp1-Cre;RANKLf/f mice, compared with control littermates.
On the basis of the cell-type specificity of the Osx1-Cre, Ocn-Cre and Dmp1-Cre transgenes 23, 25, 26 , these results suggested that RANKL produced by mature osteoblasts, but not by osteocytes or chondrocytes, is required for generating the osteoclasts that resorb the primary spongiosa during bone growth. However, hypertrophic chondrocytes highly express RANKL and have been suggested as a source of the RANKL required for calcified cartilage resorption 27, 28 . We used immunohistochemistry and found that the Ocn-Cre transgene also deleted RANKL from hypertrophic chondrocytes (Fig. 2d) . Through analysis of Osx1-Cre and Ocn-Cre mice with Rosa26-LacZ reporter (R26R) mice, we confirmed that both lead to Cre-mediated reporter gene activation in hypertrophic chondrocytes ( Supplementary Fig. 4 ).
These results indicate that deletion of RANKL in hypertrophic chondrocytes and osteoblasts (Prx1-Cre, Osx1-Cre and Ocn-Cre) but not in osteocytes (Dmp1-Cre) leads to retention of calcified cartilage. We also observed cartilage retention when RANKLf/f mice were crossed with transgenic mice expressing Cre recombinase under the control of Col10a1 regulatory elements, hereafter called collagen X (ColX)-Cre mice, which activate a reporter gene efficiently in hypertrophic chondrocytes 29 ( Supplementary Fig. 5 ). Consistent with this, RANKL immunostaining was abolished in hypertrophic chondrocytes of these mice ( Supplementary Fig. 5 ). However, analysis of ColX-Cre mice crossed with R26R reporter mice showed reporter gene activation in scattered osteoblasts and osteocytes in the distal femur ( Supplementary Fig. 5 ), suggesting that either a subset of osteoblast-lineage cells in this region sufficiently expresses the ColXCre transgene to mediate loxP recombination or that the transgene is active in a subset of osteo-chondro progenitors.
Osteocyte RANKL is essential for bone remodeling Normal resorption of the primary spongiosa, and thereby production of cancellous bone, in Dmp1-Cre;RANKLf/f mice allowed us to use this model to determine whether RANKL expression in osteocytes contributes to cancellous bone remodeling. The BMD of Dmp1-Cre;RANKLf/f mice became progressively greater than that of control littermates up to 6 months of age (Fig. 3a) , at which time cancellous bone volume in femur and spine was greater than in control littermates (Fig. 3b,c) . The abundance of the Tnfsf11 conditional allele was reduced by >70% in genomic DNA isolated from cortical bone enriched in osteocytes (Fig. 3d) . However, RANKL mRNA levels measured in whole tibia were not reduced, and only a ~40% reduction occurred in whole L5 vertebra (Fig. 3d) . This absent or small change in RANKL mRNA in whole bone, despite efficient deletion of the gene in osteocytes, suggests that the contribution of RANKL mRNA produced by osteocytes to the total RANKL mRNA in whole bone is small. Nonetheless, osteoclast number was >70% lower in femoral cancellous bone of Dmp1-Cre;RANKLf/f mice compared with control littermates (Fig. 3e) . Consistent with this, circulating markers of bone resorption and bone formation were significantly lower in Dmp1-Cre;RANKLf/f mice than in control mice (Fig. 3f) . However, the concentration of circulating soluble RANKL was similar in both groups, highlighting the importance of locally produced RANKL (Fig. 3f ) . These results suggest that RANKL produced by osteocytes is responsible for the majority of the osteoclast differentiation that drives remodeling of cancellous bone.
On the basis of our experience with the Ocn-Cre transgene, we sought to confirm the cell-type specificity of the Dmp1-Cre transgene using R26R mice. We found that, in addition to osteocytes, cells on the cancellous bone surface also had active transgene expression (Supplementary Fig. 6 ). The LacZ + cells were present on bone matrix, had morphology consistent with osteoblasts and were located on top of newly formed bone (Supplementary Fig. 6 ). These results indicate that the Dmp1-Cre transgene is active in both osteoblasts and osteocytes. Because ablation of matrix-synthesizing osteoblasts in previous studies had no effect on RANKL expression or osteoclast number 14, 15 , the reduction in RANKL and osteoclast number in our Dmp1-Cre;RANKLf/f mice must be due to loss of RANKL in osteocytes. To verify this, we reduced osteoblast number by pretreating RANKLf/f mice with osteoprotegerin, a RANKL antagonist that decreases osteoblast number by suppressing osteoclast formation and thereby bone remodeling 15 . Consistent with a decrease in a r t i c l e s osteoblast number, osteocalcin mRNA levels were reduced in bone (Supplementary Fig. 6 ). However, osteoprotegerin did not alter basal or parathyroid hormone-stimulated RANKL expression in bone, establishing that osteoblasts are not the source of RANKL (Fig. 3g) . In contrast, deletion of RANKL from both osteoblasts and osteocytes with the Dmp1-Cre transgene reduced basal and parathyroid hormone-stimulated RANKL mRNA levels (Fig. 3g) .
Osteoprogenitor RANKL does not contribute to remodeling Because deletion of RANKL in Dmp1-Cre mice did not completely eliminate osteoclasts on cancellous bone, we sought to determine whether RANKL produced by committed osteoblast progenitors has a role in osteoclast formation at this site. To do this, we suppressed expression of the Osx1-Cre transgene with doxycycline 23 . We reasoned that suppression of RANKL deletion in hypertrophic chondrocytes until 4 months of age, when the activity of the growth plate is greatly reduced, would allow the formation of normal cancellous bone architecture, and that any reduction in osteoclast formation after this time would be caused by loss of RANKL in the entire osteoblast lineage. Exposure of Osx1-Cre;RANKLf/f mice to doxycycline in utero and until 4 months of age allowed normal tooth eruption to occur, demonstrating suppression of Osx1-Cre transgene expression (Fig. 4a) . At 4 months of age, the mice were switched to a doxycycline-free diet and maintained for an additional 2 months to allow deletion of RANKL in Osx1-Cre-expressing cells. Histological analysis of femurs at 6 months of age showed a normal cancellous architecture with no evidence of cartilage retention (Fig. 4a) . RANKL deletion occurred in osteocytes (Fig. 4b ), but to a lesser extent than with the Dmp1-Cre transgene (Fig. 3d) . RANKL mRNA levels were significantly lower in whole tibia, but not in L5 vertebra, of Osx1-Cre;RANKLf/f mice compared with RANKLf/f littermates (Fig. 4b) . Notably, both basal and parathyroid hormone-stimulated RANKL mRNA levels were lower in osteoblast progenitors from Osx1-Cre;RANKLf/f mice compared with RANKLf/f mice, whereas IL-6 mRNA, used as a control, was unaffected by the deletion (Fig. 4c) . Notably, the loss of RANKL from this cell population had no effect on osteoclast number in cancellous bone, osteoclast gene expression measured in whole bones or bone mass ( Fig. 4d-f) .
Osteocyte RANKL controls unloading-induced bone loss Finally, to determine whether RANKL produced by osteocytes contributes to pathological bone resorption, we tail-suspended Dmp1-Cre;RANKLf/f mice and control littermates for 3 weeks to induce bone loss. Mice lacking RANKL in osteocytes were protected from the loss of bone and the changes in cancellous architecture caused by tail suspension (Fig. 5a,b) . In this mixed genetic background, tail suspension did not induce a significant loss of cancellous bone volume in control mice but increased trabecular spacing and decreased cortical thickness (Fig. 5b) . Consistent with the preservation of bone mass, the increase in RANKL expression that occurred in the cortical bone of tail-suspended control mice was absent in Dmp1-Cre;RANKLf/f mice (Fig. 5c) . Finally, even though tail suspension did not decrease cancellous bone volume in control mice, it did induce a small but significant increase in osteoclast number, which did not occur in Dmp1-Cre;RANKLf/f mice (Fig. 5d) .
DISCUSSION
The idea that osteoblasts or their progenitors control osteoclast formation has become a central tenet of skeletal biology and is often used to explain the linkage of bone formation to bone resorption during adult remodeling. Nonetheless, several other cell types may support osteoclastogenesis, including osteocytes 30 , vascular-associated cells 31 and lymphocytes 32 . In contrast with the prevailing dogma, our results show that osteocytes, but not osteoblasts or their precursors, are an essential cellular source of RANKL for osteoclast formation in remodeling bone. Hence, RANKL expression in osteoblast-lineage cells does not contribute to the coupling of bone formation to bone resorption because osteocytes are not generated until after bone formation is complete. Moreover, the demonstration that unloadinginduced bone loss is prevented in mice lacking RANKL in osteocytes suggests that osteocytes are crucial players in the pathogenesis of diseases caused by abnormal remodeling.
Our results also suggest that hypertrophic chondrocytes are the source of the RANKL required for resorption of the primary spongiosa. Although none of the Cre-deleter strains used in our study has activity exclusively in growth plate chondrocytes, calcified cartilage retention was associated only with transgenes that deleted RANKL from hypertrophic chondrocytes. Conversely, RANKL deletion by the Dmp1-Cre transgene, which was active in osteoblasts and osteocytes but not in chondrocytes, had no effect on cartilage resorption. Furthermore, RANKL deletion mediated by the ColX-Cre transgene prevented cartilage resorption to a similar extent as the Osx1-Cre and Ocn-Cre transgenes even though it was less effective at deleting RANKL from osteoblast-lineage cells. These findings, coupled with the robust expression of RANKL by hypertrophic chondrocytes in vivo, support a role for RANKL expression by this cell type in the resorption of calcified cartilage.
Cell preparations enriched in osteoblast progenitors express RANKL in vitro, and this expression is stimulated by hormones known to stimulate bone resorption 33, 34 . Despite this, our results show that RANKL expression in these cells does not participate in physiological bone remodeling. RANKL produced by such cells could contribute to osteoclast differentiation under different conditions, such as dietary calcium deficiency or lactation. However, RANKL expression in these cultures could also be an in vitro phenomenon and not reflect a physiological role.
Deletion of RANKL from osteocytes led to an increase in bone mass similar to that observed by pan-inhibition of RANKL in adult mice. For example, administration of denosumab, a monoclonal antibody to human RANKL, to 10-month-old human RANKL knock-in mice increased femoral cancellous bone volume by almost twofold and decreased osteoclast surface by >95% (ref. 35 ). In our study, deletion of RANKL from osteocytes increased femoral cancellous bone volume by about twofold and decreased osteoclast surface by 75%. The greater reduction in osteoclast surface by denosumab suggests either that RANKL deletion in osteocytes in our model was not complete or that RANKL produced by cells other than osteocytes also contributed to osteoclast formation. Even if the latter is the case, our results reveal that RANKL produced by osteocytes is responsible for most of the osteoclastogenesis in cancellous bone.
We expected that RANKL deletion in adult Osx1-Cre mice would reduce osteoclast number in cancellous bone to at least the same a r t i c l e s extent as RANKL deletion in Dmp1-Cre mice, as we expected both to lead to deletion from osteocytes. However, the extent of RANKL deletion in osteocyte-enriched bone was much lower in Osx1-Cre than in Dmp1-Cre mice. Although the reason for this is unclear, one possibility is that the Osx1-Cre transgene is not active in osteocytes. If this were the case, then the Tnfsf11 gene would have been deleted only in osteocytes formed during the 2 months after transgene activation. As the majority of bone growth has already occurred by 4 months of age in mice, the proportion of newly formed osteocytes lacking RANKL was probably too small to substantially reduce osteoclast formation.
A recent study using an inducible osteocyte ablation model showed that osteocyte apoptosis leads to bone resorption associated with increased RANKL expression 36 . Moreover, this study showed that osteocyte ablation prevents bone loss owing to unloading and prevents the increase in RANKL expression associated with unloading 36 . Although the latter observation is consistent with our conclusion that osteocytes are an important source of RANKL, the ablation-induced increase in RANKL expression in the grounded controls suggests that other cell types produce RANKL in this situation. An alternative explanation, supported by our findings, is that the remaining live osteocytes respond to the death of their neighboring osteocytes by increasing RANKL expression.
Our studies raise the question of how RANKL expressed by matrixembedded cells reaches osteoclast progenitors. RANKL is produced in both soluble and membrane-bound forms 37 . Osteocytes have an average of 50 cellular projections, extending throughout the bone matrix, that connect osteocytes to one another and to cells at the bone surface, forming the lacunocanalicular network 38 . Imaging studies have shown that these projections can extend beyond the bone surface so that membrane-bound RANKL expressed by osteocytes may bind osteoclast progenitors 39 . It is less clear how the membrane-bound form produced by hypertrophic chondrocytes could contact such progenitors. The soluble form of RANKL has a molecular mass of ~31 kDa (ref. 37) , which is small enough to easily pass throughout the osteocyte lacunocanalicular network 40 . Moreover, soluble proteins of similar size produced by hypertrophic chondrocytes can act in a paracrine manner 41 . Thus, production of either form of RANKL by matrix-embedded cells would be consistent with our contention that they are the predominant sources of the RANKL controlling osteoclast formation.
In conclusion, demonstration of the essential role of osteocyte-and chondrocyte-derived RANKL in osteoclastogenesis shows that these cells orchestrate resorption of the matrix in which they are embedded. This evidence provides a mechanistic explanation for the longheld view that at least some remodeling is a targeted, as opposed to stochastic, process in which cells that can sense mechanical strains 42 or matrix damage 43 act as beacons for excavation and repair of a specific region of bone. Similarly, hypertrophic chondrocytes may sense signals that initiate transformation of the cartilage scaffold into bony trabeculae. In both cases, the cells that can best detect the need for matrix removal directly control the process.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINE METHODS
Mice. We created mice harboring a Tnfsf11 conditional allele using homologous recombination in embryonic stem cells (see Supplementary Methods). We used a targeting vector in which exons 3 and 4 of the Tnfsf11 gene were flanked by loxP sites (Supplementary Fig. 1 Skeletal analysis. We obtained whole-body X-rays of anesthetized mice using an AXR 110 Minishot X-ray machine (Associated X-Ray Corporation) and measured BMD of the lumbar spine and femur by dual-energy X-ray absorptiometry using a PIXImus densitometer (GE-Lunar) and the manufacturer's software as described 45 . We measured three-dimensional bone volume and architecture of L4 vertebra and femurs using µCT (model µCT40, Scanco Medical). Details are in the Supplementary Methods. Histology. We fixed femurs for 24 h in 10% (vol/vol) Millonig's formalin, decalcified them in 14% (wt/vol) EDTA for 1 week, embedded them in paraffin and then obtained 5 µm longitudinal sections. After removal of paraffin and rehydration, we stained sections for TRAP activity or with safranin-O and counterstained them with fast green. We carried out RANKL immunostaining with an antibody to RANKL (R&D Systems) using 5 µm frozen sections of fixed and decalcified femurs. We carried out quantitative histomorphometry to determine osteoclast number using the TRAP-stained femur sections and a computer and digitizer tablet (OsteoMetrics) interfaced to a Zeiss Axioscope (Carl Zeiss) with an attached drawing tube. We directly measured the number of TRAP + cells on the cancellous perimeter (osteoclast number). We used terminology recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research 46 . Details are in the Supplementary Methods. Quantitative PCR. We harvested organs and whole bones, from which we removed soft tissues, from animals and stored them immediately in liquid nitrogen. We prepared osteocyte-enriched bone by removing the ends of femurs and tibias and then flushing the bone marrow with PBS. We then scraped the bone surface with a scalpel, after which we cut the bones into small pieces (~3 mm long), and digested the pieces with collagenase (1 mg ml −1 type I:II, ratio 1:3, Worthington Biochemical Corporation) in Hank's balanced salt solution that also contained 0.1% (wt/vol) BSA and 1 mM CaCl 2 . We carried out six consecutive 15-min digestions at 37 °C in a water bath shaker to remove the cells on the bone surface. After the final digestion, we washed the bone pieces with PBS and froze them in liquid nitrogen for later RNA isolation, or decalcified them for genomic DNA isolation. We isolated total RNA using Ultraspec reagent (Biotecx Laboratories), according to the manufacturer's instructions and prepared cDNA as described 15 . We carried out qRT-PCR using the following Taqman assays from Applied Biosystems: RANKL (Mm0041908-m1); IL-6 (Mm00446190-m1); cathepsin K (Mm01255862-g1); TRAP (Mm00475698_m1); calcitonin receptor (Mm00432271_m1); and ribosomal protein S2 (forward, 5′-CCCAGGATGGCGACGAT-3′; reverse, 5′-CCGAATGCTGTAATGGCGTAT-3′; probe, 5′-FAM-TCCAGAGCAGGATCC-NFQ-3′). We calculated relative mRNA amounts using the ∆C t method 47 . We isolated genomic DNA from decalcified bone fragments after digestion with proteinase K and phenol-chloroform extraction. We obtained two custom Taqman assays from Applied Biosystems for quantifying Tnfsf11 gene deletion efficiency, one specific for sequences between the loxP sites and the other specific for sequences downstream from the 3′ loxP site. Details are in the Supplementary Methods. Tail suspension. We carried out mechanical unloading of hindlimbs by tail suspension for 3 weeks. We suspended mice by attaching a straightened paperclip to the tail with superglue and first-aid tape, and then attaching the paperclip to a rod in the top of a modified shoe-box mouse cage. We adjusted suspension to maintain the mouse at a ~30° head-down tilt. We used fully ambulatory littermates in the same cage, separated by a divider, as controls. Details are in the Supplementary Methods.
Statistics. We used two-way ANOVA or Student's t test to detect significant treatment effects, after determining that the data were normally distributed and exhibited equivalent variances. In some cases, we used log transformation to obtain normally distributed data. All t tests were two-sided. We used Bonferroni or Holm-Sidak corrections for multiple comparisons. We considered P values <0.05 as significant. Error bars in all figures represent s.d.
Additional methods. Detailed methodology is described in the Supplementary Methods.
